BR112022008384A2 - Formulação oral de x842 - Google Patents

Formulação oral de x842

Info

Publication number
BR112022008384A2
BR112022008384A2 BR112022008384A BR112022008384A BR112022008384A2 BR 112022008384 A2 BR112022008384 A2 BR 112022008384A2 BR 112022008384 A BR112022008384 A BR 112022008384A BR 112022008384 A BR112022008384 A BR 112022008384A BR 112022008384 A2 BR112022008384 A2 BR 112022008384A2
Authority
BR
Brazil
Prior art keywords
oral formulation
relates
egerd
surfactant
treatment
Prior art date
Application number
BR112022008384A
Other languages
English (en)
Inventor
Andersson Kjell
Springfelter Mattias
Yousef Gabriella
Original Assignee
Cinclus Pharma Holding AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cinclus Pharma Holding AB filed Critical Cinclus Pharma Holding AB
Publication of BR112022008384A2 publication Critical patent/BR112022008384A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

FORMULAÇÃO ORAL DE X842. A invenção se refere a uma formulação oral de liberação imediata de X842 compreendendo apenas quantidades limitadas de tensoativo. A invenção também se refere ao uso da formulação oral no tratamento de doenças inflamatórias gastrointestinais ou doenças relacionadas com ácido gástrico, em particular doença erosiva de refluxo gastroesofágico (eGERD).
BR112022008384A 2019-11-04 2020-11-04 Formulação oral de x842 BR112022008384A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1951255 2019-11-04
PCT/EP2020/080877 WO2021089580A1 (en) 2019-11-04 2020-11-04 Oral formulation of x842

Publications (1)

Publication Number Publication Date
BR112022008384A2 true BR112022008384A2 (pt) 2022-07-12

Family

ID=73131746

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008384A BR112022008384A2 (pt) 2019-11-04 2020-11-04 Formulação oral de x842

Country Status (13)

Country Link
US (1) US20220362223A1 (pt)
EP (1) EP4054537B1 (pt)
JP (1) JP2023500904A (pt)
KR (1) KR20220097431A (pt)
CN (1) CN114901262A (pt)
AU (1) AU2020377451A1 (pt)
BR (1) BR112022008384A2 (pt)
CA (1) CA3156073A1 (pt)
ES (1) ES2949232T3 (pt)
IL (1) IL292682A (pt)
MX (1) MX2022005305A (pt)
WO (1) WO2021089580A1 (pt)
ZA (1) ZA202205756B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024530045A (ja) 2021-11-05 2024-08-14 シンクルス・ファーマ・ホールディング・アクチエボラグ リナプラザングルレート塩酸塩の多形
WO2023184282A1 (en) * 2022-03-30 2023-10-05 Guizhou Sinorda Biomedicine Co., Ltd X842 formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CN101002939A (zh) * 2007-01-12 2007-07-25 广东华南药业有限公司 一类治疗与胃酸有关疾病的药物组合制剂
FI20086158A0 (fi) * 2008-12-03 2008-12-03 Mikael Dahlstroem Imidatsopyridiinijohdannaiset
CN101816641B (zh) * 2010-03-11 2012-04-04 沈阳亿灵医药科技有限公司 一种奥美拉唑速释固体制剂及其制备方法
CN102294031B (zh) * 2011-09-07 2013-02-20 沈阳亿灵医药科技有限公司 含质子泵抑制剂、nsaid和抗酸剂的药物制剂
CN103860584B (zh) * 2014-02-25 2015-09-30 厦门恩成制药有限公司 一种奥美拉唑碳酸氢钠胶囊的制作方法
WO2016115082A1 (en) * 2015-01-12 2016-07-21 Enteris Biopharma, Inc. Solid oral dosage forms
CN106619520B (zh) * 2016-12-29 2019-08-06 南京海融制药有限公司 一种右兰索拉唑钠的干混悬剂及其制备方法

Also Published As

Publication number Publication date
AU2020377451A1 (en) 2022-05-26
CN114901262A (zh) 2022-08-12
ZA202205756B (en) 2023-10-25
MX2022005305A (es) 2022-08-16
EP4054537A1 (en) 2022-09-14
KR20220097431A (ko) 2022-07-07
CA3156073A1 (en) 2021-05-14
US20220362223A1 (en) 2022-11-17
WO2021089580A1 (en) 2021-05-14
JP2023500904A (ja) 2023-01-11
ES2949232T3 (es) 2023-09-26
EP4054537B1 (en) 2023-06-07
IL292682A (en) 2022-07-01
EP4054537C0 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
CL2020002026A1 (es) Inhibidor de fap.
CY1124084T1 (el) Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
ZA202205756B (en) Oral formulation of x842
CY1115526T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
DE602006006536D1 (de) Trockene Aripiprazolformulierungen
NO20073722L (no) Farmasoystiske sammensetniger omfattende bendamustin
CY1123137T1 (el) Ιμιδαζο[1.2α]πυριδινες για αντιμετωπιση ή προληψη υπερουριχαιμιας ή ουρικης αρθριτιδας
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
EP3943076A3 (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
CY1113257T1 (el) Παραγωγα βενζυλοπιπεραζινης τα οποια ειναι χρησιμα στη θεραπεια γαστρεντερικων διαταραχων
WO2008098985A3 (en) Pharmaceutical composition for the treatment of il-8 mediated diseases
CY1123279T1 (el) Κορτικοστεροειλη για τη θεραπεια φλεγμονωδων παθησεων της γαστρεντερικης οδου
MX2016014771A (es) Forma de dosificacion oralmente desintegrante para administracion de avanafil, y metodos de fabricacion y uso asociados.
CY1121707T1 (el) Αναστολεας πρωτεϊνης μεταφορας εστερων χοληστερολης (cetp) και φαρμακευτικες συνθεσεις που περιλαμβανουν τον εν λογω αναστολεα για χρηση στη θεραπεια ή την προληψη καρδιαγγειακων νοσηματων
EA202091533A1 (ru) Способы лечения диабета, гепатита и/или воспалительного заболевания печени
BR112012013199A2 (pt) composto, composição farmacêutica, e , uso de um composto
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
NO20073813L (no) Kladribinregime for behandling av multippel sklerose
CY1118402T1 (el) Η χρηση πηγης l3 και/ή l5 ως εμβολιου ή ως διαγνωστικου για παρασιτικη παθηση
WO2011087835A3 (en) Novel compositions and methods for treating inflammatory bowel disease and airway inflammation
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]